Ace inhibitor

The FDA ( U.S. Food and Drug Administration ) has approved Biktarvy ( Bictegravir 50mg / Emtricitabine 200mg / Tenofovir...


Dulaglutide ( Trulicity ) significantly improves A1C ( average blood sugar concentration over two to three months ) when added...


The European Commission has granted marketing authorisation for Lokelma ( formerly ZS-9, sodium Zirconium cyclosilicate ) for the treatment of...


The European Medicines Agency ( EMA ) has approved Lynparza ( Olaparib ) tablets ( 300mg twice daily ) for...


HER2 targeted therapies have substantially improved the prognosis of patients with breast cancer however they can be associated with cardiac...


Guidelines strongly recommend patients with heart failure with reduced ejection fraction ( HFrEF ) be treated with multiple medications proven...


Updated preliminary clinical data from an ongoing phase I dose escalation and expansion study evaluating the safety and efficacy of...


Data from the TRANSITION study presented at the European Society of Cardiology ( ESC ) Congress in Munich ( Germany...


Results of the global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met...


Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...


Researchers at Columbia University Medical Center ( CUMC ) have discovered that the fusion of two adjacent genes can...


Chromosomal translocations that generate in-frame oncogenic gene fusions are notable examples of the success of targeted cancer therapies. Gene fusions...


The results from the phase 3 PROSPER trial in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CRPC...


New findings were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ) in San...


The FDA ( U.S. Food and Drug Administration ) has approved Biktarvy ( Bictegravir 50mg / Emtricitabine 200mg / Tenofovir...


The FDA ( U.S. Food and Drug Administration ) has approved Nerlynx ( Neratinib ) for the extended adjuvant treatment...


The results from the one-year phase 3 CHRONOS study have shown that patients receiving the investigational drug Dupilumab ( Dupixent...



Findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke or systemic embolism and...


Evolocumab ( Repatha ), a PCSK9 inhibitor, has shown to dramatically lower levels of low-density lipoprotein ( LDL), and also...